Clene Inc. Prices $7 Million Public Offering to Fund ALS Drug Development and Address Going Concern

summarizeSummary

Clene Inc. has finalized an underwritten public offering of 1,000,000 shares at $7.00 per share, raising $7.0 million to fund its ALS drug development and address its going concern status, strategically timed after positive FDA feedback.

check_boxKey Events

• Underwritten Public Offering Priced

  Clene Inc. is offering 1,000,000 shares of common stock at a public offering price of $7.00 per share, generating gross proceeds of $7.0 million and net proceeds of approximately $6.4 million after expenses.

• Significant Dilution

  The offering will increase the number of outstanding shares by approximately 8.5%, from 11,778,307 to 12,778,307 shares, resulting in immediate and substantial dilution for existing shareholders.

• Addresses Going Concern Risk

  The capital raise is critical for the company, which has previously stated substantial doubt about its ability to continue as a going concern without additional financing.

• Funds Key Drug Development

  Proceeds will be used for general corporate purposes, including the preparation and filing of the NDA for its lead ALS drug candidate, CNM-Au8, ongoing clinical trials, manufacturing expansion, and potential future commercialization efforts.

auto_awesomeAnalysis

This prospectus supplement details a significant capital raise for Clene Inc., which is crucial given the company's previously disclosed 'going concern' risk. The offering of $7.0 million, representing approximately 9% of the company's market capitalization, provides essential funding for the preparation and filing of its New Drug Application (NDA) for the lead ALS drug candidate, CNM-Au8, as well as for ongoing clinical trials and manufacturing expansion. The timing of this offering, immediately following positive FDA feedback, suggests the company is strategically capitalizing on improved sentiment to secure necessary capital. While the offering is dilutive, it is a vital step towards extending the company's operational runway and advancing its key drug development programs.